The changing face of Staphylococcus aureus: A continuing surgical challenge

Surgical Infections

Volumn 12, Issue 3, 2011, Pages 191-203

  Fry, Donald E ^a,b   Barie, Philip S ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL ENZYME; CEFTOBIPROLE; CYTOTOXIN; DALBAVANCIN; DAPTOMYCIN; EXOTOXIN; ICLAPRIM; LINEZOLID; SUPERANTIGEN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL ENDOCARDITIS; BACTERIAL VIRULENCE; CONFERENCE PAPER; DEBRIDEMENT; HOSPITALIZATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EVOLUTION; PRIORITY JOURNAL; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CARRIER STATE; CROSS INFECTION; HUMANS; PREVALENCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURGICAL WOUND INFECTION;

EID: 80052745674     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2011.068     Document Type: Conference Paper

References (143)

1. Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenza. Br J Exp Pathol 1929;10:226-236.
2. Nespoli A, Geroulanos S, Nardone A, et al. The history of surgical infections. Surg Infect 2011;12:3-13.
3. Kirby WM. Extraction of a highly potent penicillin inactivator from penicillin resistant staphylococci. Science 1944;99:452-453.
4. Enright MC, Robinson DA, Randle G, et al. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Nat Acad Sci USA 2002;99:7687-7692.
5. Shinefield HR, Ruff NL. Staphylococcal infections: A historical perspective. Infect Dis Clin North Am 2009;23:1-15.
6. Ross G, Rodriguez W, Controni G, et al. Staphylococcal susceptibility to penicillin G: The changing pattern among community strains. JAMA 1974;229:1075-1077.
7. Udo EE, Pearman JW, Grubb WB. Genetic analysis of community isolates of methicillin-resistant taphylococcus aureus in Western Australia. J Hosp Infect 1993;25:97-08.
8. Herald BC, Immergluck LC,Maranan MC, et al. Communityacquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998;279: 593-598.
9. Vandenesch F, Naimi T, Enright MC, et al. Communityacquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: Worldwide emergence. Emerg Infect Dis 2003;9:987-994.
10. Kallen AJ, Mu Y, Bulens S, et al. Active Bacterial Core surveillance (ABCs) MRSA Investigators of the Emerging Infections Program. Health care-associated invasive MRSA infections, 2005-2008. JAMA 2010;304:641-648.
11. U.S. Centers for Disease Control and Prevention (CDC). Vital signs: Central line-associated blood stream infections- United States, 2001, 2008, and 2009. MMWR Morb Mortal Wkly Rep 2011;60:243-248.
12. Edwards JR, Peterson KD, Mu Y, et al. National Healthcare Safety Network (NHSN) report: Data summary for 2006 through 2008, issued December 2009. Am J Infect Control 2009;37:783-805.
13. Burton DC, Edwards JR, Horan TC, et al. Methicillinresistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA 2009;301:727-736.
14. Byrnes MC, Adegboyega T, Riggle A, et al. Nasal swabs collected routinely to screen for colonization by methicillinresistant Staphylococcus aureus in intensive care units are a sensitive screening test for the organism in clinical cultures. Surg Infect 2010;11:511-515.
15. Kollef MH, Barie PS. Methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization predicts intensive care unit-acquired MRSA infections: True or false? Surg Infect 2010;11:497-499.
16. Henteleff HJ, Barie PS, Hamilton SM; Members of the Evidence-Based Reviews in Surgery Group. Universal screening for methicillin-resistant Staphylococcus aureus in surgical patients. J Am Coll Surg 2010;211:833-835.
17. Harbarth S, Fankhauser C, Schrenzel J, et al. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 2008;299:1149-1157.
18. Sánchez García M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010;303:2260-2264.
19. Lindsay JA, Holden MTG. Staphylococcus aureus: Superbug, super genome? Trends Microbiol 2004;12:378-385.
20. Plata K, Rosat AE, Wegrzyn G. Staphylococcus aureus as an infectious agent: Overview of biochemistry and molecular genetics of its pathogenicity. Acta Biochim Polon 2009;56: 597-612.
21. Patti JM, Allen BL, McGavin MJ, et al. MSCRAMMmediated adherence of microorganisms to host tissues. Annu Rev Microbiol 1994;48:585-617.
22. Roche FM, Downer R, Keane F, et al. The N-terminal A domain of fibronectin-binding proteins A and B promotes adhesion of Staphylococcus aureus to elastin. J Biol Chem 2004;279:38433-38440.
23. Switalski LM, Patti JM, Butcher W, et al. A collagen receptor on Staphylococcus aureus strains isolated from patients with septic arthritis mediates adhesion to cartilage. Mol Microbiol 1993;7:99-107.
24. McDevitt D, Nanavaty T, House-Pompeo K, et al. Characterization of the interaction between the Staphylococcus aureus clumping factor (ClfA) and fibrinogen. Eur J Biochem 1997;247:416-424.
25. Ni Eidhin D, Perkins S, Francois P, et al. Clumping factor B (ClfB), a new surface-located fibrinogen-binding adhesion of Staphylococcus aureus. Mol Microbiol 1998;30:245-257.
26. Hartleib J, Kohler N, Dickinson RB, et al. Protein A is the von Willebrand factor binding protein on Staphylococcus aureus. Blood 2000;96:2149-2156.
27. Park PW, Broekelmann TJ, Mecham BR, Medham RP: Characterization of the elastin binding domain in the cellsurface 25-kDa elastin-binding protein of Staphylococcus aureus (EbpS). J Biol Chem 1999;274:2845-2850.
28. Tung H, Buss B, Hellman U, et al. A bone sialoproteinbinding protein from Staphylococcus aureus: A member of the staphylococcal Sdr family. Biochem J 2000;345:611-619.
29. Clarke SR, Harris LG, Richards RB, Foster SJ. Analysis of Ebh, a 1.1 megadalton cell wall-associated fibronectinbinding protein of Staphylococcus aureus. Infect Immun 2002;70:6680-6687.
30. Hauck CR, Ohlsen K. Sticky connections: Extracellular matrix protein recognition and integrin-mediated cellular invasion by Staphylococcus aureus. Curr Opin Microbiol 2006;9:5-11.
31. Gordon RJ, Lowy FD. Pathogenesis of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2008;46: S350-S359.
32. Otto M. Staphylococcal biofilms. Curr Top Microbiol Immunol 2008;322:207-228.
33. Weigel LM, Donlan RM, Shin DH, et al. High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm. Antimicrob Agents Chemother 2007; 51:231-238.
34. Chavakis T, Wiechmann K, Preissner KT, Herrmann M. Staphylococcus aureus interactions with the endothelium: The role of bacterial 'Secretable Expanded Repertoire Adhesive Molecules' (SERAM) in disturbing host defense systems. Thromb Haemost 2005;94:278-285.
35. McDevitt D, Vaudaux PE, Foster TJ. Genetic evidence that bound coagulase of Staphylococcus aureus is not clumping factor. Infect Immun 1992;60:1514-1523.
36. Panton PN, Valentine FCO. Staphylococcal toxin. Lancet 1932;1:506-508.
37. Otto M. Basis of virulence in community-associated methicillin- resistant Staphylococcus aureus. Annu Rev Microbiol 2010;64:143-162.
38. Burnside K, Lembo A, de los Reyes M, et al. Regulation of hemolysin expression and virulence of Staphylococcus aureus by a serine/threonine kinase and phosphatase. PLoS One 2010;5:e11071.
39. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton- Valentine leukocidin and highly lethal necrotizing pneumonia in young immunocompetent patients. Lancet 2002; 359:753-759.
40. Wang R, Braughton KR, Kretschmer D, et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 2007;13:1510-1514.
41. Balaban N, Rasooly A. Staphylococcal enterotoxins. Int J Food Microbiol 2000;61:1-10.
42. Nishifuji K, Sugai M, Amagai M. Staphylococcal exfoliative toxins: 'Molecular scissors' of bacteria that attack the cutaneous defense barrier in mammals. J Dermatol Sci 2008; 49:21-31.
43. Lappin E, Ferguson AJ. Gram-positive toxic shock syndromes. Lancet Infect Dis 2009;9:281-290.
44. Larkin EA, Carman RJ, Krakauer T, Stiles BG. Staphylococcus aureus: The toxic presence of a pathogen extraordinaire. Curr Med Chem 2009;16:4003-4019.
45. Rivera J, Vannakambadi G, Höök M, Speziale P. Fibrinogen- binding proteins of gram-positive bacteria. Thromb Haemost 2007;98:503-511.
46. Bokarewa MI, Jin T, Tarkowski A. Staphylococcus aureus: Staphylokinase. Int J Biochem Cell Biol 2006;38:504-509.
47. Hart ME, Hart MJ, Roop AJ. Genotypic and phenotypic assessment of hyaluronidase among type strains of a select group of staphylococcal species. Int J Microbiol 2009;2009: 614371.
48. Cotton FA, Hazen EE Jr, Legg MJ. Staphylococcal nuclease: Proposed mechanism of action based on structure of enzyme-thymidine 3¢,5¢- bisphosphate-calcium ion complex at 1.5-Å resolution. ProcNatAcad SciUSA 1979;76:2551-2555.
49. Jacobsson G, Colque-Navarro P, Gustafsson E, et al. Antibody responses in patients with invasive Staphylococcus aureus infections. Eur J Clin Microbiol Infect Dis 2010; 29:715-725.
50. Burlak C, Hammer CH, Robinson MA, et al. Global analysis of community-associated methicillin-resistant Staphylococcus aureus exoproteins reveals molecules produced in vitro and during infection. Cell Microbiol 2007;9:1172-1190.
51. McDougal LK, Steward CD, Killgore GE, et al. Pulsedfield gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: Establishing a national database. J Clin Microbiol 2003;41: 5113-5120.
52. Ito T, Okuma K, Ma XX, et al. Insights on antibiotic resistance of Staphylococcus aureus from its whole genome: Genomic island SCC. Drug Resist Update 2003;6:41-52.
53. Daum RS, Ito T, Hiramatsu K, et al. A novel methicillin resistance cassette in community-acquired methicillinresistant Staphylococcus aureus isolates of diverse genetic backgrounds. J Infect Dis 2002;186:1344-1347.
54. Rehm SJ. Staphylococcus aureus: The new adventures of a legendary pathogen. Cleve Clin J Med 2008;75:177-180.
55. Diep BA, Chambers HF, Graber CJ, et al. Emergence of multidrug- resistant, community-acquired, methicillin-resistant Staphylococcus aureus cloneUSA300 inmenwho have sex with men. Ann InternMed 2008;148:249-257.
56. Hawley PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother 2009;64(Suppl):i3-i10.
57. U.S. Centers for Disease Control and Prevention. Reduced susceptibility of Staphylococcus aureus to vancomycin: Japan, 1996. Morb Mort Wkly Rep1997;46:624-626.
58. Sader HS, Moet GJ, Farrell DJ, Jones RN. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: Trend analysis of a 6-year period in U.S. medical centers (2005-2010). Diagn Microbiol Infect Dis 2011 May 3. [Epub ahead of print]
59. Cervera C, Almela M, Martínez-Martínez JA, et al. Risk factors and management of gram-positive bacteraemia. Int J Antimicrob Agents 2009;34(Suppl 4):S26-S30.
60. Patel N, Pai MP, Rodvold KA, et al. Vancomycin: We can't get there from here. Clin Infect Dis 2011;52:969-974.
61. Hageman JC, Patel JB, Carey RC, et al. Investigation and control of vancomycin-intermediate and-resistant Staphylococcus aureus: A guide for health departments and infection control personnel. Atlanta, Georgia. U.S. Centers for Disease Control and Prevention, 2006. Available at www.cdc.gov/ncidod/dhqp/ar- visavrsa-prevention.html Accessed May 12, 2011.
62. Tenover FC. The quest to identify heterogeneously resistant vancomycin-intermediate Staphylococcus aureus strains. Int J Antimicob Agents 2010;36:303-306.
63. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am J Med 2006;119(Suppl 6A):S3-S10.
64. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001;7:327-332.
65. Walsh TR, Bolmstöm A, Qwä rnström A, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001;39:2439-2444.
66. Plipat N, Livni G, Bertram H, Thomson RB Jr. Unstable vancomycin heteroresistance is common among clinical isolates of methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005;43:2494-2496.
67. Walsh TR, Howe RA. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu Rev Microbiol 2002;56:657-675.
68. Khatib R, Jose J, Musta A, et al. Relevance of vancomycinintermediate susceptibility andheteroresistance inmethicillinresistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2011 Apr 26 [Epub ahead of print].
69. Cheong JW, Harris P, Oman K, Norton R. Challenges in the microbiological diagnosis and management of hVISA infections. Pathology 2011 May 2 [Epub ahead of print].
70. U.S. Centers for Disease Control and Prevention. CDC reminds clinical laboratories and healthcare infection preventionists of their role in the search and containment of vancomycin-resistant Staphylococcus aureus (VRSA), May 2010. Available at www.bt.cdc.gov/coca/reinders/2010/2010may06.asp Accessed December 7, 2010.
71. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260-2266.
72. Itani KM, Dryden MS, Bhattacharyya H. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2010;199:804-816.
73. Wunderink RG, Cammarata SK, Oliphant T, et al. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003;25:980-992.
74. Powers JH, Ross DB, Lin D, et al. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: The subtleties of subgroup analysis. Chest 2004;126:314-315.
75. Sievert DM, Rudrik JT, Patel JB, et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008;46:668-674.
76. Gold HS, Pillai SK. Antistaphylococcal agents. Infect Dis Clin North Am 2009;23:99-131.
77. Finks J, Wells E, Dyke TL, et al. Vancomycin-resistant Staphylococcus aureus, Michigan, USA, 2007. Emerg Infect Dis 2009; 15:943-945.
78. Medscape. Vancomycin IV. Available at www.medscape .com/druginfo/ pricebrandimage?cid=med&drugid=939&drugname =Vancomycin + IV&monotype = pricebrandimage Accessed December 7, 2010.
79. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: Summary of clinical experience. Antimicrob Agents Chemother 2002;46:2723-2726.
80. Noskin GA, Rubin RJ, Schentag JJ, et al. The burden of Staphylococcus aureus infections on hospitals in the United States: An analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch Intern Med 2005;165:1756-1761.
81. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin- resistant Staphylococcus aureus infections in the United States. JAMA 2007;298:1763-1771.
82. De Kraker ME, Wolkewitz M, Davey PG, Grundmann H;BURDEN Study Group. Clinical impact of antimicrobial resistance in European hospitals: Excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother 2011;55:1598-1605.
83. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality with methicillin-resistant and methicillinsusceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 2003;36:53-59.
84. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592-598.
85. Eagye KJ, Kim A, Laohavaleeson S, et al. Surgical site infections: Does inadequate antibiotic therapy affect patient outcomes? Surg Infect 2009;10:323-331.
86. Laupland KB, Church DL, Mucenski M, et al. Populationbased study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. J Infect Dis 2003; 187:1452-1459.
87. Jacobsson G, Dashti S, Wahlberg T, et al. The epidemiology of and risk factors for invasive Staphylococcus aureus infections in western Sweden. Scand J Infect Dis 2007:39:6-15.
88. Henteleff HJ, Barie PS, Hamilton SM, et al., and members of the Evidence-Based Reviews in Surgery Group. Canadian Association of General Surgeons and American College of Surgeons evidence-based reviews in surgery: Universal screening for methicillin-resistant Staphylococcus aureus in surgical patients. J Am Coll Surg 2010;211:833-835.
89. Ammerlaan HS, Kluytmans JA, Burkhout H, et al.; on behalf of the MRSA Eradication Study Group. Eradication of carriage with methicillin-resistant Staphylococcus aureus: Effectiveness of a national guideline. J Antimicrob Chemother 2011 June 30 [Epub ahead of print].
90. Ammerlaan HS, Kluytmans JA, Burkhout H, et al.; on behalf of the MRSA Eradication Study Group. Eradication of carriage with methicillin-resistant Staphylococcus aureus: Determinants of treatment failure. J Antimicrob Chemother 2011 June 30 [Epub ahead of print].
91. Evans HL, Dellit TH, Chan J, et al. Effect of chlorhexidine whole-body bathing on hospital-acquired infections among trauma patients. Arch Surg 2010;145:240-246.
92. Fukatsu K, Saito H, Matsuda T, et al. Influences of type and duration of antimicrobial prophylaxis on an outbreak of methicillin-resistant Staphylococcus aureus and on the incidence of wound infection. Arch Surg 1997;132:1320-1326.
93. Falagas ME, Alexiou VG, Pappas G, Makris GC. Do changes in antimicrobial resistance necessitate reconsideration of surgical antimicrobial prophylaxis strategies? Surg Infect 2009;10:557-562.
94. Chambers D, Worthy G, Myers L, et al. Glycopeptide vs. nonglycopeptide antibiotics for prophylaxis of surgical site infections: A systematic review. Surg Infect 2010;11:455-462.
95. Rosenberger LH, Politano AD, Sawyer RG. The Surgical Care Improvement Project and prevention of postoperative infection, including surgical site infection. Surg Infect 2010;12:163-168.
96. Miller LG, McKinnell JA, Vollmer ME, Spellberg B. Impact of methicillin-resistant Staphylococcus aureus prevalence among S. aureus isolates on surgical site infection risk after coronary artery bypass surgery. Infect Control Hosp Epidemiol 2011;32:342-350.
97. Bratzler DW, Houck PM for the Surgical Infection Prevention Guideline Writers Workgroup: Antimicrobial prophylaxis for surgery: An advisory statement from the National Surgical Infection Prevention Project. Am J Surg 2005;189:395-404.
98. Finkelstein R, RabinoG,Mashiah T, et al. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thoracic Cardiothorac Surg 2002;123:326-332.
99. Sweet FA, Roh M, Silva C. Intra-wound application of vancomycin for prophylaxis in instrumented thoracolumbar fusions: Efficacy, drug levels, and patient outcomes. Spine 2011 Feb 7 [Epub ahead of print].
100. Buttaro MA, Guala AJ, Comba F, et al. Incidence of deep infection in aseptic revision THA using vancomycin-impregnated impacted bone allograft. Hip Int 2010;20:535-541.
101. Furuya EY, Dick A, Perencevich EN, et al. Central line bundle implementation in US intensive care units and impact on bloodstream infections. PLoS One 2011;6:e15452.
102. Sihler KC, Chenoweth C, Zalewski C, et al. Catheter-related vs. catheter-associated blood stream infections in the intensive care unit: Incidence, microbiology, and implications. Surg Infect 2010;11:529-534.
103. U.S. Centers for Disease Control and Prevention. Vital signs: Central line-associated blood stream infections- United States, 2001, 2008, and 2009. MMWR Morb Mortal Wkly Rep 2011;60:243-248.
104. Edwards JR, Peterson KD, Mu Y, et al. National Healthcare Safety Network (NHSN) report: Data summary for 2006 through 2008, issued December 2009. Am J Infect Control 2009;37:783-805.
105. May AK, Stafford RE, Bulger EM, et al.; Surgical Infection Society. Treatment of complicated skin and soft tissue infections. Surg Infect 2009;10:467-499.
106. May AK. Skin and soft tissue infections: The new Surgical Infection Society guidelines. Surg Infect 2011;12:179-184.
107. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. Community- associated meticillin-resistant Staphylococcus aureus. Lancet 2011;375:1557-1568.
108. Collage RD, Rosengart MR. Abdominal wall infections with in situ mesh. Surg Infect 2010;11:311-318.
109. Rybak MJ, Lomaestro BM, Rotschaefer JC, et al. Vancomycin therapeutic guidelines: A summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49:325-327.
110. LiuC, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the InfectiousDiseases Society ofAmerica for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52:e18-e55.
111. Gonzalez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillinsusceptible organisms. Clin Infect Dis 1999; 29:1171-1177.
112. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996;38:865-869.
113. Stryjewski ME, Szczech LA, Benjamin DK Jr, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin- susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007;44:190-196.
114. Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia: Recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine 2003;82:333-339.
115. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260-2266.
116. Itani KM, Dryden MS, Bhattacharyya H. Efficacy and safety of linezolid vs. vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2010;199:804-816.
117. Wunderink RG, Cammarata SK, Oliphant T, et al. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003;25:980-992.
118. Powers JH, Ross DB, Lin D, et al. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: The subtleties of subgroup analysis. Chest 2004;126:314-315.
119. Gold HS, Pillai SK. Antistaphylococcal agents. Infect Dis Clin North Am 2009;23:99-131.
120. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: Summary of clinical experience. Antimicrob Agents Chemother 2002;46:2723-2726.
121. Sánchez García M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010;303:2260-2264.
122. Tally FP,DeBruinMF.Development of daptomycin for grampositive infections. J Antimicrob Chemother 2000;46:523-526.
123. Bassetti M, Nicco E, Ginocchio F, et al. High-dose daptomycin in documented Staphylococcus aureus infections. Int J Antimicrob Agents 2010;36:459-461.
124. Nailor MD, Sobel JD. Antibiotics for gram-positive bacterial infections: Vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. Infect Dis Clin North Am 2009;23:965-982.
125. Miller BA, Gray A, Leblanc TW, et al. Acute eosinophilic pneumonia secondary to daptomycin: A report of three cases. Clin Infect Dis 2010;50:e63-e68.
126. Nannini E, Murray BE, Arias CA. Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol 2010;10:516-521.
127. Rose W, Rybak M. Tigecycline: First of a new class of antimicrobial agents. Pharmacotherapy 2006;26:1099-1110.
128. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skinstructure infections: Results of 2 double-blind Phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41(Suppl 5):S341-S353.
129. Towfigh S, Pasternak J, Poirier A, et al. A multicentre, openlabel, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections. Clin Microbiol Infect 2010;16:1274-1281.
130. Food and Drug Administration. U.S. Department of Health and Human Services. FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. September 1, 2010. Available at www.fda.gov/Drugs/Drug- Safety/ucm224370.htm Accessed December 7, 2010.
131. Cai Y, Wang R, Liang B, et al. Systematic review and metaanalysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011;55:1162-1172.
132. Guskey MT, Tsuji BT. A comparative review of the lipoglycopeptides: Oritavancin, dalbavancin, and telavancin. Pharmacotherapy 2010;30:80-94.
133. Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006;50:862-867.
134. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005;41:407-415.
135. Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003;37:1257-1260.
136. Sincak CA, Schmidt JM. Iclaprim, a novel diaminopyrimidine for the treatment of resistant gram-positive infections. Ann Pharmacother 2009;43:1107-1114.
137. Dauner DG, Nelson RE, Taketa DC. Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin- resistant Staphylococcus aureus. Am J Health Syst Pharm 2010;67:983-993.
138. Steed ME, Rybak MJ. Ceftaroline: A new cephalosporin with activity against resistant gram-positive pathogens. Pharmacotherapy 2010;30:375-389.
139. Noel GJ, Bush K, Bagchi P, et al. A randomized, doubleblind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin structure infections. Clin Infect Dis 2008;46:647-655.
140. Corey GR, Wilcox MH, Talbot GH, et al. CANVAS 1: The first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010;65(Suppl 4):iv41-iv51.
141. Wilcox MH, Corey GR, Talbot GH, et al. CANVAS 2: The second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010;65(Suppl 4):iv53-iv65.
142. Altemeier WA, Hummel RP, Hill EO. Staphylococcal enterocolitis following antibiotic therapy. Ann Surg 1963;157:847-857.
143. Lin Z, Kotler DP, Schlievert PM, Sordillo EM. Staphylococcal enterocolitis: Forgotten but not gone? Dig Dis Sci 2010;55:1200-1207.